VICTOR
ASENSI ALVAREZ
Catedrático de Universidad
Hospital Universitario Virgen de la Victoria
Málaga, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (21)
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
2021
-
Mural Endocarditis: The GAMES Registry Series and Review of the Literature
Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764
2018
-
Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 268-276
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Overall and cause-specific excess mortality in HIV-positive persons compared with the general population Role of HCV coinfection
Medicine (United States), Vol. 95, Núm. 36
2015
-
Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2014
-
Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)
Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2009
-
The Spanish HIV BioBank: A model of cooperative HIV research
Retrovirology, Vol. 6
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2007
-
Cervical lipomatosis in HIV-infected patients: A case-control study
HIV Medicine, Vol. 8, Núm. 1, pp. 17-21
-
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study
AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241